State Pharmacy Rules for Compounded Ketamine

The medication used in most telehealth ketamine programs is compounded ketamine—not an FDA-approved product, but a ketamine formulation custom-prepared by a licensed compounding pharmacy. State pharmacy regulations governing compounded controlled substances add another layer to the already complex access landscape. Understanding these rules helps explain why some patients have access to at-home ketamine and others do not.

What Is Compounded Ketamine?

The FDA has approved ketamine for use as an anesthetic (under brand names including Ketalar). It has not approved ketamine for depression, anxiety, or PTSD. The sublingual troches, oral formulations, and nasal sprays used in telehealth ketamine programs are therefore compounded preparations—medications custom-made by a licensed compounding pharmacy for an individual patient pursuant to a prescription.

Compounding pharmacies are legally permitted to prepare these formulations, provided they comply with applicable state and federal regulations. The specific ketamine formulations used in telehealth programs (particularly sublingual troches) are not available as off-the-shelf pharmaceutical products and exist specifically because of the compounding system.

Federal Compounding Oversight: 503A vs. 503B

Federal law divides compounding pharmacies into two categories:

503A Pharmacies (Traditional Compounding)

503A pharmacies compound medications for individual patients pursuant to valid prescriptions. They are regulated primarily by state pharmacy boards. They can compound ketamine troches, oral solutions, nasal sprays, and other formulations for individual patients.

503B Outsourcing Facilities

503B facilities produce compounded preparations in larger quantities without individual patient prescriptions. They are registered with the FDA and subject to Current Good Manufacturing Practice (cGMP) standards. Some 503B facilities produce ketamine preparations used in clinical settings.

Most telehealth ketamine programs work with 503A compounding pharmacies—the traditional compounding model where each prescription triggers preparation for the specific patient.

State Pharmacy Licensing and Interstate Shipping

The Core Rule

A pharmacy must be licensed in the state where the patient resides to legally ship medication to that patient. This is the critical geographic constraint on compounded ketamine access.

If you are in Massachusetts and the compounding pharmacy the telehealth platform works with is licensed in California, that pharmacy must also hold a Massachusetts pharmacy license to ship your ketamine there.

Major compounding pharmacies that partner with telehealth ketamine platforms are typically licensed in most or all states specifically to support interstate shipping.

Verifying Pharmacy Licensure

You can verify a compounding pharmacy's license in your state through your state pharmacy board's license verification portal. Most state boards maintain searchable online databases. If you want to confirm that your ketamine is coming from a legitimately licensed pharmacy, this is how you do it.

State-Level Compounding Restrictions

Some States Restrict Compounding of Certain Controlled Substances

A small number of states have enacted additional restrictions on compounding controlled substances, beyond the federal framework. These restrictions may:

• Limit the quantities of compounded Schedule III substances that can be dispensed
• Require additional documentation or physician attestation
• Restrict certain formulations that are not used in any FDA-approved product

These state-level restrictions can create access barriers even when federal law and DEA prescribing regulations are fully complied with.

USP Standards and Controlled Substance Compounding

The United States Pharmacopeia (USP) publishes standards for pharmaceutical compounding, including Chapter 795 (non-sterile preparations) and Chapter 797 (sterile preparations). Sublingual troches are non-sterile preparations governed by USP 795. State boards of pharmacy generally adopt USP standards, and compounding pharmacies must comply with them.

States have varying levels of enforcement rigor for USP compliance, which can affect the quality consistency of compounded preparations across pharmacies.

Quality Considerations for Compounded Ketamine

Unlike FDA-approved drugs, compounded preparations are not subject to the same manufacturing consistency requirements. Quality can vary between compounding pharmacies. Well-regarded pharmacies follow USP standards rigorously, submit to third-party testing, and maintain quality control programs. Less rigorous operations may produce formulations with variable potency or purity.

When evaluating a telehealth ketamine platform, it is worth asking which compounding pharmacy they use and what quality standards that pharmacy maintains. Our what to look for in a provider guide covers how to assess platform quality, including pharmacy partnerships. Reputable platforms partner with established, high-quality compounding pharmacies precisely because medication consistency affects clinical outcomes.

Notable compounding pharmacies serving the telehealth ketamine market include Belmar Pharmacy, Empower Pharmacy, and Woodland Hills Pharmacy, among others. These pharmacies have established reputations and serve patients in most states.

The FDA and Compounded Ketamine

The FDA has expressed interest in ketamine compounding, particularly as the telehealth ketamine market has grown. The agency has the authority to add drugs to its "Difficult to Compound" list or otherwise restrict compounding of specific drugs if it determines that public health concerns warrant it.

Compounded ketamine has not been added to the FDA's "Inappropriate Compounding" category, and there is no current FDA action targeting compounded ketamine specifically. However, the FDA's ongoing oversight of compounding means this landscape could change.

What This Means for Patients

For most patients seeking telehealth ketamine, pharmacy-level regulations operate invisibly—platforms handle pharmacy selection and licensing compliance on the back end. But understanding these rules helps in several ways:

1. If your state is not served: The reason may be pharmacy licensing rather than prescriber licensing. Ask the platform specifically.
2. If you receive a formulation that seems different than expected: Contact both your provider and the pharmacy. Compounded medications can vary between pharmacy batches, and questions about potency or consistency should be addressed promptly.
3. If you are considering changing platforms: Your prescription is specific to one prescriber and one pharmacy. If you change platforms, you will need a new prescription and will receive medication from a potentially different pharmacy.
4. Storage and handling: Compounded medications should be stored as directed (typically refrigerated for certain formulations). Unlike pharmaceutical manufacturing, compounding does not include the extended shelf-life stability data FDA-approved products undergo.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• HHS: Telehealth — U.S. Department of Health and Human Services guide to telehealth services, regulations, and patient resources
• SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service